Title: Everything You Need to Know About Clinical Trials Registration and Results Reporting Requirements
1Everything You Need to Know About Clinical
Trials Registration and Results Reporting
Requirements
- Deborah A. Zarin, M.D.
- ClinicalTrials.gov
- October 2009
1
1
2Background
3Recent Events
February 27, 2009
4February 26, 2009
5Kaplan-Meier estimates for ulcer complications
according to traditional definition. Results are
truncated after 12 months, no ulcer complications
occurred after this period. Adapted from Lu 2001.
Source Jüni P, Rutjes AW, Dieppe PA. BMJ. 2002
Jun 1324(7349)1287-8.
6Zarin DA, Tse T. Medicine. Moving toward
transparency of clinical trials. Science. 2008
Mar 7319(5868)1340-2.
7Levels of Transparency
7
Zarin DA, Tse T.. Science. 2008 Mar
7319(5868)1340-2.
8Reasons to Register Clinical Trials and Report
Results
- Human Subject Protections
- Allows potential participants to find studies
- Assists ethical review boards and others to
determine appropriateness of studies being
reviewed (e.g., harms, benefits, redundancy) - Promote fulfillment of ethical responsibility to
human volunteers research contributes to
medical knowledge - Research Integrity
- Facilitates tracking of protocol changes
- Increases transparency of research enterprise
- Evidence Based Medicine
- Facilitates tracking of studies and outcome
measures - Allows for more complete identification of
relevant studies - Allocation of Resources
- Promotes more efficient allocation of resources
9ClinicalTrials.govthe basics
10History of ClinicalTrials.gov
- FDAMA 113 (1997) Mandates Registry
- IND trials for serious and life-threatening
diseases or conditions - ClinicalTrials.gov Launched in February 2000
- Calls for Increased Transparency of Clinical
Trials - Maine State Law State Attorneys General
- Journal Editors (2004)
- ClinicalTrials.gov Accommodates Other Policies
- FDAAA 801 (2007) Expands Registry and Adds
Results Database
10
10
10
11New Registrations Continue to Increase
11
12ClinicalTrials.gov Statistics (as of 10/05/09)
- Number Percent
- Total 79,605 100
- Type of Trial
- Observational 12,956 16
- Interventional 66,649 83
- Drug Biologic 54,208
- Surgical Procedure 8,470
- Behavioral, Gene
- Transfer, Other 13,369
- Device 4,742
- International Sites (172 countries)
- US only 37,271 47
- Non-US only 28,263 35
- US Non-US mixed 5,686 7
- Missing 8,385 11
12
12
231 delayed posting device trials included in
total, but excluded from other statistics
13ClinicalTrials.gov Statistics (cont.)(as of
10/05/09)
Number Percent
Trials by Sponsor US Federal (including
NIH) 10,777 14 Industry 25,737
32 University, Other 43,091 54
Total 79,605
User Statistics Page Views per month 60
Million Unique visitors per month 900,000
13
13
14(No Transcript)
15(No Transcript)
16(No Transcript)
17(No Transcript)
18(No Transcript)
19(No Transcript)
20(No Transcript)
21(No Transcript)
22Value-Added Links
23(No Transcript)
24(No Transcript)
25(No Transcript)
26(No Transcript)
27Search Interface
28(No Transcript)
29(No Transcript)
30(No Transcript)
31(No Transcript)
32Legal and other requirements
33ICMJE Policy
- Editorial 2004 and updates
- Registration required for manuscript
consideration for following - Interventional studies
- Any phase
- Any intervention
- ClinicalTrials.gov or WHO Primary registry
- Registration prior to enrollment first participant
34Public Law 110-85Sec.801 Expanded Clinical Trial
Registry
- Enacted on September 27, 2007
- Requires Trial Registration (Dec 2007)
- Phase II-IV drug and device trials for all
diseases - Data elements ClinicalTrials.gov WHO/ICMJE
- Requires Results Reporting (Sept 2008)
- Trials of FDA-approved or cleared drugs and
devices - Basic Results Baseline Characteristics,
Primary Secondary Outcomes, Statistical
Analyses - Adverse Events (Sept 2009)
- Expansion of results by rulemaking (Sept 2010)
- Added enforcement provisions
34
34
34
34
35Enforcement Provisions
- Notices of non-compliances
- Civil monetary penalties up to 10,000/day
- Withholding of NIH grant funds
36(No Transcript)
37Key Terms
- Applicable Clinical Trials
- Interventional trials
- Phase 2-4 drug, biologic, device
- gt one site in U.S.
- Ongoing as of 9/27/07, or later
- Responsible Party
- Sponsor, grantee
- PI if designated
- Primary Completion Date
38Key Milestones FDAAA - Sec.801 Expanded
Clinical Trial Registry
- December 26, 2007
- New registration requirements effective
- Linking to existing results
- September 27, 2008
- Basic Results reporting requirements effective
- April 2009 - Public Meeting
- September 27, 2009 Adverse Events
- September 27, 2010 Rulemaking Due
38
39Key Points Memo from Dr. Kington, Acting
Director, to NIH Grant Awardess
- For grants, NIH is generally not the sponsor
and, as such, NIH would not be the responsible
party. - Responsible parties who have not yet registered
their clinical trials should do so immediately. - Thank you for your attention to this important
matter and your commitment to helping enhance the
transparency of NIH funded clinical trials.
40Basic Results Database
40
41Basic Results Database General Characteristics
- Results of applicable clinical trials of
FDA-approved/cleared medical products - Generally, submission within 12 months of the
earlier of estimated or actual trial completion
date (of primary outcome) - Delayed Submission of Results
- Seeking initial approval
- Seeking approval of a new use
- Extensions for good cause
41
41
41
41
41
42Adverse Events
- If the Secretary fails to issue regulation by
March 2009, default provisions take effect in
September 2009 - SERIOUS ADVERSE EVENTS
- Table of anticipated unanticipated serious
adverse events - Grouped by organ system
- Number and frequency of event in each clinical
trial arm - FREQUENT (other) ADVERSE EVENTS
- Table of anticipated unanticipated adverse
events - Exceed a frequency of 5 percent within any trial
arm - Grouped by organ system
- Number and frequency of event in each trial arm
42
42
42
42
42
43Basic Results Modules
- Participant Flow
- Baseline and Demographic Characteristics
- Outcome Measures
- Adverse Events (summary data)
- Other Information
- Certain Agreements Restricting Results
Disclosure - Overall Limitations and Caveats
- Results Point of Contact
44Current Status Basic Results(as of 02/06/09)
- Functional Web-based Data Entry System
- Launched in September 2008
- 662 Results Records have been submitted
- Industry 449 records from gt 100 data providers
- NIH 24 records
- Rate of submission continues to increase
- 40 records per week now
- Anticipate about 150 per week
44
44
45Sample Posted Results
45
45
45
46Participant Flow
- A table ..., including the number of patients
who dropped out of the clinical trial and the
number of patients excluded from the analysis, if
any. - Sec. 282(j)(3)(C)(i)
47Reasons Not Completed
An Investigational Drug on Clinical Outcomes in
Patients With Aortic Stenosis NCT00092677
47
48Arms
Milestone
Reasons Not Completed
48
49Baseline Measures
- A table of the demographic and baseline data
collected overall and for each arm of the
clinical trial - Sec. 282(j)(3)(C)(i)
50Default Required Measures
User-Specified Measure
Categories
51Outcome Measure
- a table of values for each of the primary and
secondary outcome measures for each arm of the
clinical trial - Sec. 282(j)(3)(C)(ii)
5252
5353
54(No Transcript)
55Categories
56Statistical Analysis
- a table of values for each of the primary and
secondary outcome measures, including the
results of scientifically appropriate tests of
the statistical significance of such outcome
measures. - Sec. 282(j)(3)(C)(ii)
57Statistical Analysis
57
58Statistical Analysis
59Statistical Analysis
60Serious Adverse Events
- A table of anticipated and unanticipated serious
adverse events grouped by organ system, with
number and frequency of such event in each arm of
the clinical trial. - Sec. 282(j)(3)(I)(iii)(I)
61Frequent Adverse Events
- A table of anticipated and unanticipated adverse
events that are not included in the Serious
Adverse Events table that exceed a frequency
of 5 percent within any arm of the clinical
trial, grouped by organ system, with number and
frequency of such event in each arm of the
clinical trial. - Sec. 282(j)(3)(I)(iii)(II)
61
62Definition of Adverse Event
- Definition Unfavorable changes in health,
including abnormal laboratory findings, that
occur in trial participants during the clinical
trial or within a specified period following the
trial.
63Definition of Serious AE
- Serious Adverse Events include adverse events
that result in death, require either inpatient
hospitalization or the prolongation of
hospitalization, are life-threatening, result in
a persistent or significant disability/incapacity
or result in a congenital anomaly/birth defect. - Other important medical events, based upon
appropriate medical judgment, may also be
considered Serious Adverse Events if a trial
participant's health is at risk and intervention
is required to prevent an outcome mentioned.
6464
6565
66(No Transcript)
67Design Features
- Tables are constructed by the data provider
- Columns are pre-set as study arms, but can be
changed by the data provider - Rows are measuressome are pre-set, others are
customized for each study - Type of measure determines specific design of
cells - Attempt to balance fixed structure with
flexibility
67
68http//prsinfo.clinicaltrials.gov/fdaaa.html
68
68
69(No Transcript)
70(No Transcript)
71Issues in Reporting Results
72ICJME
- will not consider results posted in the same
primary clinical trials register in which the
initial registration resides as previous
publication if the results are presented in the
form of a brief, structured (lt500 words) abstract
or table.
72
73Who is the Audience?
PI and Clinical Research Team Other Medical
Researchers in same field Other Medical
Researchers in other fields Other Readers of the
medical literature Science Writers Lay Public
(readers of consumer health literature)
74Quality Assurance Challenges
- Data tables will be the public representation of
the studymust be clear and informative - NLM QA Focuses on
- Apparent Validity (when possible)
- Meaningful Entries
- Internal consistency/logic
- Format
75What Does QA Address?
- Data must make sense
- Measure name, units, and data must match
- No invalid entries
- E.g., 823 hours/day time to survival
- No illogical tables
- No missing parameters or data
- Tables should convey study design, conduct and
analysis
76Tables Must Be Informative
- Scales should include
- Full name
- Construct or domain (e.g., pain)
- Direction of scores (Best/Worst Value)
- Other information as necessary
- Measures Have Useful Descriptions
- Avoid Abbreviations
77 Measure Information Must be Precise and Accurate
- Avoid misuse of terms, e.g.,
- proportion
- ratio
- incidence
- State what is being measured and how
- Do not provide results in measure description
field
78 Data in All Tables Must be Internally Consistent
and Logical
- Participants must flow
- Number analyzed must be consistent with
participant flow data - Avoid Illogical Entries
79Illogical Results Table
Drug X, Week 10 Drug X, Change from Week 10 to 18
Number of Participants Analyzed units participants 88 80
Treatment Satisfaction QuestionnaireAfter 18 Weeks of Treatment units Score Mean Standard Deviation 81 17.46 7.9 12.16
79
79
79
80Unclear Outcome Measure
Measure Name Time to Disease-Free Survival
Measure Description Time from date of treatment to date of survival
Time Frame 5 years
Drug A Drug B
Number of Participants Analyzed units participants 648 645
Time to Disease-Free Survival units participants 246 277
80
81Problematic Entry
Intervention X Control
Number of Participants Analyzed units participants 28 27
Hours Per Day of Sleep units Average Hours per Day Mean Standard Deviation 823 92 864 106
81
81
81
82Problematic Entry
Measure Name Clinician Assessment After Injection
Measure Description Physicians assessment of SIJ pain 5 point-Likert scale, Change of finger to floor cm and Schober test mm
Time Frame 8 months
Sacroiliac Injection
Number of Participants Analyzed units participants 29
Clinician Assessment After Injection units Units on a scale 100
82
83Informative Entry
Measure Name Pregnancy Rate (Pearl Index)
Measure Description Pearl Index (100)(number of pregnancies)(4 cycles/year)/number of 91-day cycles completed.
Time Frame After the onset of treatment and within 14 days after the last combination pill (approx. 1 year of treatment)
DR-1011
Number of Participants Analyzed 1735
Pregnancy Rate (Pearl Index) units Pregnancies per 100 woman years exposure 2.74
83
84Informative Entry
Measure Name Time to Progressive Disease
Measure Description Time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.
Time Frame Every other 21 day cycle (6-8 cycles) and every 3 months during follow-up
Drug X
Number of Participants Analyzed 50
Time to Progressive Disease units weeks Median ( 95 Confidence Interval ) 45.1 ( 37.9 to 56.9 )
84
85Number of Results Recordswithout Revision by
Quarter Posted
106
Number of Records Posted Without Revision
27
10
8
85
Quarter Posted
86Results Posting - Caveats
- Posting does not assure that all review criteria
were met - Data provider is responsible for ensuring that
records meet review criteria - ClinicalTrials.gov may note issues and request
revisions after results have been posted publicly
- Additional comments may suggest improvements, but
are not necessarily required changes prior to
posting
87Lessons Learned from Early Submissions of Basic
Results
- Data Providers must be able to understand the
study design and data analysis - Typically, the investigator and a statistician
will need to be involved
87
88Interesting Scientific Issues
89Interventional vs. Observational
- Interventional studies in human beings in which
individuals are assigned by an investigator based
on a protocol to receive specific interventions.
Subjects may receive diagnostic, therapeutic or
other types of interventions. The assignment of
the intervention may or may not be random. The
individuals are then followed and biomedical
and/or health outcomes are assessed. - Observational studies in human beings in which
biomedical and/or health outcomes are assessed in
pre-defined groups of individuals. Subjects in
the study may receive diagnostic, therapeutic, or
other interventions, but the investigator does
not assign specific interventions to the subjects
of the study.
90Interventional or Observational?
- Example Evaluation of PillCam Colon Capsule
Endoscopy (PCCE) in the Visualization of the
Colon - Capsule Endoscopy versus Colonoscopy for the
Detection of Polyps and Cancer - Van Gossum et al. NEJM (2009)
91Interventional (as of 8/3/09)
91
92Observational (before 8/3/09)
92
93How Should You Describe the Outcome Measures?
Level of Detail
Low
- Anxiety
- Hamilton Anxiety Rating Scale
- Hamilton Anxiety Rating Scale at 12 weeks
- Change in Hamilton Anxiety Rating Scale at 12
weeks from baseline - Proportion of patients with improvement in
Hamilton Anxiety Rating Scale at 12 weeks from
baseline -
- Proportion of participants with a change of 11
points at 12 weeks from Baseline on the Hamilton
Anxiety Rating Scale
High
94Goals for Registration of Outcome Measures
- Inform potential participants
- Provide details to inform other researchers,
systematic reviewers, etc. - Monitor integrity of research
- Track additions/deletions
- Track significant changes
94
95CLASS Study Data by Follow-up Period
Kaplan-Meier estimates for ulcer complications
according to traditional definition. Results are
truncated after 12 months, no ulcer complications
occurred after this period. Adapted from Lu 2001.
Source Jüni P, Rutjes AW, Dieppe PA. BMJ. 2002
Jun 1324(7349)1287-8.
96ENHANCE Prespecified Endpoints
2
1
3
Source Kastelein JJ et al. Am Heart J. 2005
Feb149(2)234-9.
97Bottom LineReporting Outcome Measures
- Be as specific as possible
- Primary and Secondary outcome measures
- Designation should be consistent with statistical
analysis plan - Other prespecified and post hoc should be
used for measures that are not in the statistical
analysis plan
98Outcome Measure Statistics ClinicalTrials.gov
(as of 8-27-09)
- 701 Results records posted
- 1,592 POMs
- Mean 2.3
- Median 1
- Range 1-71
- 3,402 Secondary OMs
- 498 Results records with 1
- Mean 5
- Median 2
- Range 0-85
Other Pre-specified 43 Records, 156 OMs,
Range 1-31 Post-Hoc 11 Records, 18 OMs,
Range 1-6
99Diagnostic Accuracy Studies
- Studies in which the results are generally
displayed in a 2 x 2 table - Columns with disease and without disease
based on a reference standard - Rows test positive and test negative based
on the experimental diagnostic test. - ClinicalTrials.gov can be used to create 2 x 2
tables
100Applicable Clinical Trials?
- Components involve devices and/or drugs
- ImageChecker DMax computer-aided detection
system, version 8.1 (Hologic/R2 Technology)
Gilbert FJ et al. N Engl J Med 20083591675-84.
101Device or Procedure?
- What Is the Intervention Type?
- Device
- Procedure/Surgery
- Example The Stress Incontinence Surgical
Treatment Efficacy Trial - Burch Colposuspension versus Fascial Sling to
Reduce Urinary Stress Incontinence - Albo ME et al. NEJM (2007)
102Procedure Burch Modified Tanagho Procedure
Autologous Fascia Sling
103Bottom Line
- Determine who is the Responsible Party
- Register prior to enrollment (or within 21d)
- Phase 2-4 interventional trials that include a
drug, device or biologic - Regardless of whether or not the trial is being
used to support an FDA application - Report results
- Any trial described above once the drug, device
or biologic has been approved OR - Within one year of primary completion date
- Keep all information up to date!
103
104Next Steps
- September 27, 2010 Expansion by Rulemaking
- Expect announcement in October about plans for
rulemaking
105Key Issues in Expansion
- Expand results reporting to trials of unapproved
products? - Include narrative summaries? Can it be done
w/out being promotional and misleading? - Technical
- Lay Language
- Data Quality Verification
- Process (e.g., Pilot Quality Control Project)
- External Sources
- Full protocol versus extract necessary to help
evaluate the results
105
106EMEA Unapproved Products
- Publically Accessible Results Database
- Required no later than 6 months after trial
completion (i.e., last patient, last visit) - Applies to EU-regulated clinical trials of
medicines, regardless of authorization status - Applies to trials of pediatric and adult drugs
- Interaction to harmonize EudraCT and
ClinicalTrials.gov databases policies
107Resources
108Finding Results at ClinicalTrials.gov
- From Homepage
- Go to Search for Clinical Trials
- Select Advanced Search
- Select Studies with Results from the menu for
the Study Results field - Select study record from results list
- Click Study Results tab
108
108
109109
109
110110
110
111111
111
112112
112
113Additional Information(at http//prsinfo.clinical
trials.gov/fdaaa.html)
- "Basic Results" Data Element Definitions
- Helpful Hints - tips on entering results data,
including examples of common study models (e.g.,
crossover design) - Detailed Review Items - describes items
evaluated by the QA/QC staff at NLM - Common Errors - overview of common types of
errors identified in submitted records with
"basic results"
113
113
113
113
113
114Additional Background
- Tse T, Williams RJ, Zarin DA. Update on
registration of clinical trials in
ClinicalTrials.gov. Chest 2009136304-5. - Tse T, Williams RJ, Zarin DA. Reporting basic
results in ClinicalTrials.gov. Chest
2009136295-303. - Zarin DA, Tse T. Moving toward transparency of
clinical trials. Science 20083191340-2. - Wood AJ. Progress and deficiencies in the
registration of clinical trials. N Engl J Med
2009360824-30.
115Additional Information
- Email LISTSERV and other FDAAA information
- http//prsinfo.clinicaltrials.gov/fdaaa.html
- Other general information
- http//prsinfo.clinicaltrials.gov
- Questions?
- register_at_clinicaltrials.gov
115
115
115
115
115